Your session is about to expire
← Back to Search
Bevacizumab for Glioblastoma
Study Summary
This trial is testing a new way to give chemotherapy to people with a certain type of brain tumor. The hope is that it will help them live longer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 45 Patients • NCT02036424Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had IV chemotherapy in the last 3 weeks or radiation in the last 4 weeks.My blood counts are within a healthy range.I am not pregnant or breastfeeding.My grade IV brain tumor has come back after being completely removed.My diagnosis is glioblastoma.I am older than 18 years.It has been over four weeks since my last surgery.I can care for myself and am expected to live for at least three more months.
- Group 1: Intra Arterial Bevacizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper threshold of individuals involved in this research?
"Affirmative. Per information found on clinicaltrials.gov, this clinical trial is actively seeking out enrollees and was first posted June 1st 2014 with the last update occuring August 8th 2022. Altogether, 30 patients are needed from a single medical centre for participation in this study."
What medical conditions has Bevacizumab been found to assist with?
"Bevacizumab is traditionally used to treat cancer, however it can also be taken for conditions such as recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer after the initial surgery and locally advanced nonsquamous non-small cell lung cancers."
Have there been further investigations concerning Bevacizumab?
"Currently, 355 investigations are being conducted using Bevacizumab. Out of these, 89 have reached the third clinical trial phase. Although the majority of trials take place in Taibei, Taiwan, a total of 17017 sites actively participate in this research effort."
Are there any open opportunities for individuals to participate in this trial?
"Affirmative. Clinicaltrials.gov provides documentation that this clinical study, which was first posted in June 2014, is presently recruiting for 30 individuals at one medical site. The trial has been most recently updated on August 8th 2022."
What potential risks can be associated with the administration of Bevacizumab?
"With only a limited amount of data available to evaluate its safety and efficacy, bevacizumab was assigned the lowest score on our scale – 1."
Share this study with friends
Copy Link
Messenger